Solid Biosciences shares surge 14.07% intraday after FDA grants rare pediatric designation for SGT-212 and Needham initiates Buy rating with $16 target.

Solid Biosciences Inc. surged 14.07% intraday trading following multiple positive developments. The stock’s rally aligned with the company securing FDA Rare Pediatric Disease Designation for SGT-212, a gene therapy for Friedreich’s Ataxia, and FDA Fast Track Designation for SGT-501, a first-in-class gene therapy for Catecholaminergic Polymorphic Ventricular Tachycardia. Additionally, Needham initiated coverage with a “Buy” rating and a $16 price target, citing SGT-003’s potential to reduce liver toxicity while maintaining efficacy. These regulatory milestones and analyst optimism highlighted the company’s competitive positioning amid safety concerns with rival therapies, driving immediate investor confidence.